Better Choice’s Halo Pet Food Brand Awarded "2022 Consumer’s Favorite Imported Cat Brand" by the China Pet Industry White Paper

By adminMarch 19, 2023Global News Feed

After polling over 30,000 pet owners in China, Halo was voted as one of the top picks in the imported cat food category After polling over 30,000 pet owners in China, Halo was voted as one of the top picks in the imported cat food category

Read the rest here:
Better Choice’s Halo Pet Food Brand Awarded "2022 Consumer’s Favorite Imported Cat Brand" by the China Pet Industry White Paper

CancerVax Universal Cancer Vaccine Being Developed by UCLA

By adminMarch 19, 2023Global News Feed

The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells. The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells.

Read this article:
CancerVax Universal Cancer Vaccine Being Developed by UCLA

argenx Announces Annual General Meeting of Shareholders on May 2, 2023

By adminMarch 19, 2023Global News Feed

March 17, 2023

See the original post here:
argenx Announces Annual General Meeting of Shareholders on May 2, 2023

GENETWORx Looking to acquire or partner with Diagnostic Laboratories

By adminMarch 19, 2023Global News Feed

King of Prussia, PA, March 17, 2023 (GLOBE NEWSWIRE) -- GENETWORx, a private equity backed laboratory, announces it’s looking to buy or partner with other diagnostics laboratories.

Original post:
GENETWORx Looking to acquire or partner with Diagnostic Laboratories

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

By adminMarch 19, 2023Global News Feed

BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2022, highlighted recent program progress, and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

Read the original:
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

Celyad Oncology to announce full year 2022 financial results and host conference call

By adminMarch 19, 2023Global News Feed

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd.

Read this article:
Celyad Oncology to announce full year 2022 financial results and host conference call

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

By adminMarch 19, 2023Global News Feed

WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA, March 17-21) new data from its INTEGUMENT-1 and INTEGUMENT-2 pivotal Phase 3 studies of roflumilast cream 0.15% in adults and children 6 years and older with mild to moderate atopic dermatitis (AD). Roflumilast cream is a once-daily, steroid-free topical formulation of a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor.

Visit link:
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

By adminMarch 19, 2023Global News Feed

ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2 RAPIDe-1 study of PHVS416 for the on-demand treatment of attacks at the 2023 HAEi Regional Conference APAC, taking place in Bangkok, Thailand, on March 17-19, 2023.

Follow this link:
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot…

By adminMarch 19, 2023Global News Feed

More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks

Read the original here:
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot...

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand…

By adminMarch 19, 2023Global News Feed

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

View original post here:
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand...